Clinical Trial Update: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection [Phase 2]

View source ↗

Summary

This completed Phase 2 trial evaluated inhaled AP-PA02 for safety, phage kinetics, and efficacy in non-cystic fibrosis bronchiectasis with chronic Pseudomonas a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• AP-PA02

Snippet

Sponsor: Armata Pharmaceuticals, Inc. | Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa | Phase 2 | Status: COMPLETED | Results posted: 2026-01-05